The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-120757
- Objectives: The aim of this study was to evaluate the efficiency of cetuximab-based anti-EGFR treatment and Aurora kinase A / B knockdown as a function of Aurora kinase polymorphism in HNSCC cell lines. Materials and methods: First, protein expression of Aurora kinase A / B and EGFR and Aurora kinase A polymorphism were studied in tumour samples. The survival and proliferation of Aurora kinase A homo- (Cal27) and heterozygous (HN) HNSCC cell lines was evaluated using a colony formation assay and a flow cytometric assay. Also, aneuploidy wasObjectives: The aim of this study was to evaluate the efficiency of cetuximab-based anti-EGFR treatment and Aurora kinase A / B knockdown as a function of Aurora kinase polymorphism in HNSCC cell lines. Materials and methods: First, protein expression of Aurora kinase A / B and EGFR and Aurora kinase A polymorphism were studied in tumour samples. The survival and proliferation of Aurora kinase A homo- (Cal27) and heterozygous (HN) HNSCC cell lines was evaluated using a colony formation assay and a flow cytometric assay. Also, aneuploidy was determined. EGFR signalling pathway were visualised by western blotting. Results: Immunohistochemistry revealed the overexpression of Aurora kinase A / B in HNSCC. The knockdown of each kinase caused a significant decrease in clonogenic survival, independent of Aurora kinase A polymorphism. In contrast, cetuximab treatment impaired clonogenic survival only in the Aurora kinase A-homozygous cell line (Cal27). Conclusion: This study provides in vitro evidence for the predictive value of Aurora kinase A polymorphism in the efficiency of cetuximab treatment. Resistance to cetuximab treatment can be overcome by simultaneous Aurora kinase A/B knockdown.…
Autor(en): | Anja Pickhard, Michael Siegl, Alexander Baumann, Maximilian Huhn, Markus Wirth, Rudolf Reiter, Martina Rudelius, Guido Piontek, Gero Brockhoff |
---|---|
URN: | urn:nbn:de:bvb:20-opus-120757 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Pathologisches Institut |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Oncotarget |
Erscheinungsjahr: | 2014 |
Band / Jahrgang: | 5 |
Heft / Ausgabe: | 14 |
Seitenangabe: | 5428-38 |
Originalveröffentlichung / Quelle: | Oncotarget, Vol. 5, No. 14., p. 5428-38 |
PubMed-ID: | https://pubmed.ncbi.nlm.nih.gov/24980817 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | HNSCC; aurora kinase A polymorphism; aurorakinase B; cetuximab |
Datum der Freischaltung: | 16.02.2016 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung |